MX2018005946A - Metodo de modificacion de diferenciacion e inmunidad de macrofagos. - Google Patents
Metodo de modificacion de diferenciacion e inmunidad de macrofagos.Info
- Publication number
- MX2018005946A MX2018005946A MX2018005946A MX2018005946A MX2018005946A MX 2018005946 A MX2018005946 A MX 2018005946A MX 2018005946 A MX2018005946 A MX 2018005946A MX 2018005946 A MX2018005946 A MX 2018005946A MX 2018005946 A MX2018005946 A MX 2018005946A
- Authority
- MX
- Mexico
- Prior art keywords
- immunity
- hom
- monocyte
- macrophage differentiation
- polypeptide
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title abstract 4
- 230000004069 differentiation Effects 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 210000001616 monocyte Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000001420 Homeobox domains Human genes 0.000 abstract 1
- 108050009606 Homeobox domains Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01003—Homoserine dehydrogenase (1.1.1.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Un método para tratar un cáncer, el método comprende: proporcionar un macrófago o monocito genéticamente modificado que contiene una secuencia de ácido nucleico que codifica un polipéptido Hom-1 o un fragmento del mismo que contiene el dominio homeobox Hom-1, en donde la secuencia de ácido nucleico está operablemente unida a un promotor heterólogo y el macrófago o monocito modificado expresa el polipéptido Hom-1 o el fragmento del mismo; y administrar el macrófago o monocito modificado a un sujeto con cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562253836P | 2015-11-11 | 2015-11-11 | |
PCT/US2016/061310 WO2017083508A1 (en) | 2015-11-11 | 2016-11-10 | Method of modifying macrophage differentiation and immunity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005946A true MX2018005946A (es) | 2019-01-14 |
Family
ID=58695305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005946A MX2018005946A (es) | 2015-11-11 | 2016-11-10 | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20180325949A1 (es) |
EP (2) | EP3973968A3 (es) |
JP (2) | JP7191377B2 (es) |
KR (1) | KR20180094883A (es) |
CN (2) | CN115957239A (es) |
AU (2) | AU2016353064B2 (es) |
CA (1) | CA3003877A1 (es) |
DK (1) | DK3374497T3 (es) |
ES (1) | ES2896762T3 (es) |
IL (1) | IL259089A (es) |
MX (1) | MX2018005946A (es) |
SG (2) | SG11201803599PA (es) |
WO (1) | WO2017083508A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210007914A (ko) * | 2019-07-12 | 2021-01-20 | 고려대학교 산학협력단 | M1 대식세포를 유효성분으로 포함하는 광열치료 효과 증진용 조성물 |
CN111388670A (zh) * | 2020-03-20 | 2020-07-10 | 天津大学 | 基于脂多糖的矿化普鲁士蓝光免疫制剂的合成方法 |
CN111558039A (zh) * | 2020-03-20 | 2020-08-21 | 天津大学 | LPS@CuS:Gd光免疫剂的合成方法 |
KR102268963B1 (ko) * | 2020-05-04 | 2021-06-24 | 이종균 | 머신러닝 기법으로 말초혈액 내 암 면역력을 평가하여 암을 진단하거나 치료반응을 예측하는 방법 및 이를 이용한 진단키트 |
KR102511633B1 (ko) * | 2022-08-09 | 2023-03-20 | 오가노이드사이언스 주식회사 | M1 마크로파지 및 m2 마크로파지 혼합물을 이용한 항암제 효능 평가 방법 |
WO2023043278A1 (ko) * | 2021-09-17 | 2023-03-23 | 오가노이드사이언스 주식회사 | 항암제 효능 평가 또는 스크리닝 방법 |
AU2022367285A1 (en) * | 2021-10-15 | 2024-05-02 | Zhenglun Zhu | Method of cancer treatment |
WO2023172642A1 (en) * | 2022-03-08 | 2023-09-14 | Whitehead Institute For Biomedical Research | Compositions and methods of a high-throughput screen to identify compounds that alter macrophage-mediated cytotoxicity of target cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035790A1 (en) * | 1999-01-15 | 2003-02-20 | Shu-Hsia Chen | Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject |
US20080248011A1 (en) * | 2004-01-27 | 2008-10-09 | Medical And Biological Laboratories Co., Ltd. | Methods for Isolating Monocytes |
ES2707590T3 (es) * | 2009-07-15 | 2019-04-04 | Zhenglun Zhu | Gestión del tratamiento de trastornos inflamatorios o autoinmunitarios usando expresión de Hom-1 |
US20150297679A1 (en) * | 2012-12-14 | 2015-10-22 | The Brigham And Women's Hospital, Inc. | Methods and assays relating to macrophage differentiation |
-
2016
- 2016-11-10 CA CA3003877A patent/CA3003877A1/en active Pending
- 2016-11-10 MX MX2018005946A patent/MX2018005946A/es unknown
- 2016-11-10 WO PCT/US2016/061310 patent/WO2017083508A1/en active Application Filing
- 2016-11-10 SG SG11201803599PA patent/SG11201803599PA/en unknown
- 2016-11-10 CN CN202211644341.3A patent/CN115957239A/zh active Pending
- 2016-11-10 ES ES16864994T patent/ES2896762T3/es active Active
- 2016-11-10 AU AU2016353064A patent/AU2016353064B2/en active Active
- 2016-11-10 SG SG10201913133WA patent/SG10201913133WA/en unknown
- 2016-11-10 KR KR1020187016334A patent/KR20180094883A/ko not_active Application Discontinuation
- 2016-11-10 EP EP21189242.7A patent/EP3973968A3/en active Pending
- 2016-11-10 DK DK16864994.5T patent/DK3374497T3/da active
- 2016-11-10 CN CN201680066221.6A patent/CN108495931A/zh active Pending
- 2016-11-10 EP EP16864994.5A patent/EP3374497B1/en active Active
- 2016-11-10 JP JP2018524771A patent/JP7191377B2/ja active Active
- 2016-11-10 US US15/774,809 patent/US20180325949A1/en not_active Abandoned
-
2018
- 2018-05-02 IL IL259089A patent/IL259089A/en unknown
-
2021
- 2021-09-02 US US17/465,266 patent/US20210393682A1/en not_active Abandoned
-
2022
- 2022-11-30 JP JP2022190869A patent/JP2023022205A/ja active Pending
-
2023
- 2023-03-20 AU AU2023201694A patent/AU2023201694A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023022205A (ja) | 2023-02-14 |
EP3973968A2 (en) | 2022-03-30 |
DK3374497T3 (da) | 2021-11-01 |
KR20180094883A (ko) | 2018-08-24 |
CA3003877A1 (en) | 2017-05-18 |
CN108495931A (zh) | 2018-09-04 |
SG10201913133WA (en) | 2020-03-30 |
EP3374497A1 (en) | 2018-09-19 |
JP2018534305A (ja) | 2018-11-22 |
EP3973968A3 (en) | 2022-06-08 |
ES2896762T3 (es) | 2022-02-25 |
AU2023201694A1 (en) | 2023-04-20 |
SG11201803599PA (en) | 2018-05-30 |
JP7191377B2 (ja) | 2022-12-19 |
US20210393682A1 (en) | 2021-12-23 |
EP3374497B1 (en) | 2021-08-04 |
CN115957239A (zh) | 2023-04-14 |
US20180325949A1 (en) | 2018-11-15 |
AU2016353064A1 (en) | 2018-05-24 |
AU2016353064B2 (en) | 2022-12-22 |
IL259089A (en) | 2018-06-28 |
EP3374497A4 (en) | 2019-04-10 |
WO2017083508A1 (en) | 2017-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018005946A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
MY190034A (en) | Method of treating cancer associated with a ras mutation | |
EP4219561A3 (en) | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies | |
MY193723A (en) | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
MX2018011425A (es) | Construcciones de anticuerpos de adn y método para utilizarlas. | |
MX2018005145A (es) | Terapia genetica. | |
MX2022001085A (es) | Anticuerpos anti-c1s humanizados y metodos para usarlos. | |
TR201909037T4 (tr) | Yeni protein deamidaz. | |
MX2023009421A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
MX2020003508A (es) | Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. | |
MX2023010076A (es) | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. | |
MY183321A (en) | Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same | |
MX2016011465A (es) | Drimenol-sintasas y metodos para producir drimenol. | |
PH12018501070A1 (en) | Anti-pcsk9 antibody and use thereof | |
PH12017501678A1 (en) | Recombinant microorganism for improved production of finie chemicals | |
AR100789A1 (es) | Métodos y composiciones para proporcionar suspensión y consolidación de apuntalantes en operaciones de tratamiento subterráneo | |
MX2020002852A (es) | Tratamiento mejorado de dermatitis atopica con tradipitant. | |
MY183061A (en) | Polypeptides having xylanase activity with a high conversion rate of xylose-containing polysaccharides | |
MX2017002390A (es) | Anticuerpos anti-vasa y metodos de produccion y uso de los mismos. | |
MX2016011300A (es) | Vectores recombinantes del virus isfahan. | |
MX2019006090A (es) | Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos. |